Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06636617 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

177Lu-JH04 in Patients with FAP-Positive Tumors

Name: 177Lu-JH04 in Patients with FAP-Positive Tumors — clinical trial record (NCT06636617)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhaseEarly Phase 1

SponsorFirst Affiliated Hospital of Fujian Medical University

Started2024-08-21

View on ClinicalTrials.gov ↗

Record status

This record was last updated October 10, 2024 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.

First Affiliated Hospital of Fujian Medical University

56 trials monitored

See all monitored trials

This is a pilot study to assess the dosimetry, toxicity and response of 177Lu-JH04, a new FAP-targeted radiopharmaceutical, in patients with FAP-Positive Tumors. All patients underwent 68Ga-FAPI PET/CT for selection and were successively divided into three groups of 3 people each.The three groups received successively an approximately 3.70 GBq (100 mCi), 5.55 GBq (150 mCi) and 7.40 GBq (200 mCi) of 177Lu-JH04 up to 4 cycles.

Trial Details

NCT Number	NCT06636617
Lead Sponsor	First Affiliated Hospital of Fujian Medical University
Conditions	Patients with Advanced Metastatic FAP-Positive Tumors
Enrollment	9 participants
Start Date	2024-08-21
Primary Completion	2025-08-31 (estimated)
Study Completion	2025-08-31 (estimated)
Updated on ClinicalTrials.gov	2024-10-10